HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Personnel Growth Could Have Plateaued For Drugs Program

This article was originally published in The Tan Sheet

Executive Summary

Only a handful of new FTEs are requested in President Obama’s FY 2016 budget request for human drugs activities, suggesting that GDUFA and other related programs may have reached their critical mass of employees for now.

You may also be interested in...



FDA’s Rent Is Too Damn High: Consolidated Labs Cost More Than Off-Campus Space

After moving thousands of employees from leased off-campus space to the new Life Sciences-Biodefense Laboratory at its White Oak headquarters, FDA is paying 23% more in rent.

FDA Field Operations Would Endure Reductions Under Budget

President Obama’s FY 2016 blueprint includes cuts to ‘low-priority’ enforcement, surveillance and other activities in FDA human drugs and biologics programs, but still increases those operations overall.

Show Me The Money: FDA Recruitment Efforts Challenged By Government Salaries

FDA’s Center for Drugs continues to operate under a staffing shortage at a time when it faces tremendous pressure to implement new authorities. In some cases, that’s left Janet Woodcock scrambling to find senior managers that can lead top CDER initiatives. Direct hiring authority has helped, but it doesn’t fully address FDA’s recruiting challenges. There’s still too much red tape – and not enough money.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS123344

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel